Giritinib significantly increases survival odds in patients with FLT3-mutated acute myeloid leukemia

Gilitinib (Gilteritinib), as an innovative targeted therapy, has shown remarkable efficacy in the treatment of patients with FLT3 mutated acute myeloid leukemia (AML) in recent years. FLT3gene mutations are the most common type of AML, and the prognosis of such patients is usually poor. The introduction of giritinib not only provides patients with a new treatment strategy, but also significantly improves the patient's survival probability.

FLT3 mutations are mainly divided into two types: internal tandem repeats (ITD) and tyrosine kinase domain (TKD) point mutations. These mutations lead to abnormal activation of the FLT3 receptor, thereby promoting the proliferation of leukemia cells. By specifically inhibiting the activity of the FLT3 receptor, giritinib blocks abnormal signaling pathways and effectively controls the development of leukemia. This mechanism makes giritinib an ideal therapeutic drug for patients with FLT3 mutated AML.

Multiple clinical studies have confirmed the efficacy of gilitinib in patients with FLT3 mutated AML. In particular, in a pivotal phase 3 clinical trial, giritinib was directly compared with salvage chemotherapy, and the results showed the significant advantages of giritinib.

Specifically, in this trial, patients with FLT3mutated relapsed or refractory AML were divided into two groups, with one receiving giritinib and the other receiving salvage chemotherapy. The study results showed that the median progression-free survival time of the giritinib group was 2.8 months, which was significantly higher than the 0.7 months of the chemotherapy group. At the same time, the proportion of patients who achieved complete remission in the gilitinib group was also significantly higher than that in the chemotherapy group. These data fully demonstrate the significant efficacy of giritinib in the treatment of patients with FLT3 mutated AML.

In addition, giritinib has been shown to be effective against two common FLT3 mutations - FLT3-ITD and F The inhibitory effect of LT3-TKD further enhances its therapeutic status in patients with FLT3mutationsAML.

The safety of giritinib has also been fully verified in clinical trials. Although some patients may experience some adverse reactions, these reactions are generally expected and can be controlled with appropriate medical management. Compared with traditional chemotherapy drugs, giritinib has relatively minor side effects, significantly improving patients' quality of life.

The emergence of geritinib provides a new treatment option for FLT3 mutated AML patients. Its unique targeting mechanism makes giritinib expected to become one of the standard treatments for newly diagnosed patients in the future. At the same time, giritinib is also expected to be used in combination with other drugs to produce better therapeutic effects. With the continuous deepening of clinical research and the progress of drug development, we expect that giritinib can bring better therapeutic effects and quality of life to more AML patients in the future.

Most importantly, giritinib significantly increased the odds of survival in patients with FLT3mutationsAML. In one clinical trial, patients treated with giritinib had a median overall survival of 9.3 months, compared with 5.6 months in the control group. This data fully illustrates the significant effect of giritinib in prolonging patient survival. At the same time, giritinib can also increase the complete remission rate of patients and further improve the prognosis of patients.